New 'Living Drug' trial seeks to fight tough blood cancers
Disease control
Recruiting now
This is an early-stage study to find a safe dose and check the initial safety of a new CAR-T cell therapy called GF-CART01. It is for adults aged 18-70 with certain advanced B-cell blood cancers that have come back or not responded to at least two prior treatments. The therapy in…
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 03:41 UTC